Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Atorvastatin: From Mevalonate to Ferroptosis
2026-08-25
Atorvastatin is more than an HMG-CoA reductase inhibitor: it is a versatile probe for connecting cholesterol metabolism, vascular remodeling, and ferroptosis. This guide translates recent hepatocellular carcinoma findings into practical assay and model-selection decisions.
-
Minocycline HCl as a Microglial Test of Translation
2026-08-25
Minocycline HCl can do more than suppress inflammation: used carefully, it can reveal whether microglial activity is required for stimulus-driven amyloid clearance. This translational perspective connects the 40-Hz retinal flicker findings with rigorous reagent selection, assay design, and development strategy.
-
HMGB1 and Early Diabetic Nephropathy: Proteomic Evidence
2026-08-24
This iScience study combines quantitative serum proteomics, Mfuzz trajectory clustering, and WGCNA to identify proteins associated with diabetic nephropathy progression. HMGB1 was prioritized as a potential early-monitoring biomarker and was further supported by cell and animal experiments performed under high-glucose conditions, although prospective clinical validation remains necessary.
-
CENPO, Prognosis, and Immunity in Lung Adenocarcinoma
2026-08-24
This study identifies CENPO as a superenhancer-associated oncogenic factor linked to poor prognosis, immune dysregulation, and aggressive behavior in lung adenocarcinoma. By integrating TCGA and GEO analyses with chromatin visualization and cell-based validation, it proposes the CENPO-associated prognostic signature as a potentially useful framework for risk stratification and mechanistic studies.
-
Wnt agonist 1 in Wnt–GPX4 Assay Design
2026-08-23
Wnt agonist 1 (BML-284) offers a defined pharmacological input for studying β-catenin–TCF signaling and its possible relationship to GPX4-linked platinum resistance. This article focuses on causal assay design, evidence boundaries, and translational limitations rather than repeating a standard activation protocol.
-
40-Hz Flicker and Retinal Amyloid Clearance
2026-08-22
A 2026 mouse study reports that 40-Hz light flicker enhances retinal amyloid-β clearance through regulation of MHC-II-positive microglia. The work connects sensory stimulation with immune-mediated waste removal and uses minocycline inhibition to test whether microglial activity is required for improved retinal function.
-
Tetracycline: From Ribosome Tool to Translation
2026-08-21
Tetracycline is more than a routine antibiotic selection reagent. This thought-leadership article examines its ribosomal mechanism, experimental value, translational boundaries, and strategic use alongside mechanistic cancer research such as LKB1-driven senescence in lung adenocarcinoma.
-
Fingolimod and the Next Frontier of Immune Trafficking
2026-08-20
Fingolimod (FTY720) offers translational researchers more than an established multiple sclerosis mechanism: it is a controlled perturbation of lymphocyte positioning. When considered alongside magnetic bispecific nano-antibody platforms for in vivo CAR-T-mimicking cell generation, its value lies in helping researchers separate immune-cell availability, tumor infiltration, and per-cell antitumor function.
-
Cyclosporin A: From Mechanism to Translation
2026-08-20
Cyclosporin A is more than a calcineurin inhibitor. Its cyclophilin-dependent biology, membrane behavior, and variant-specific mitochondrial activity provide a practical framework for designing more predictive immunology and mitochondrial studies.
-
KN-62 Workflows for CaMKII Signaling
2026-08-19
KN-62 enables controlled interrogation of CaMKII-dependent calcium signaling in secretion, metabolism, and cell-cycle assays. This guide pairs practical dosing and troubleshooting with an orthogonal channel-pharmacology framework drawn from neuronal electrophysiology.
-
Sulfo-Cy3 NHS Ester in Vascular Translation
2026-08-19
Translational vascular research increasingly depends on methods that preserve biomolecular behavior while making complex mechanisms visible. This article examines how Sulfo-Cy3 NHS ester, a hydrophilic fluorescent dye for amino-group labeling, can support mechanistic studies of the AIBP–LRP2–HDL–miR-223–CXCR4 axis and help researchers build more reproducible workflows from conjugation chemistry to vascular phenotyping.
-
N-Formimidoyl Thienamycin: Comparative Antibacterial Evidenc
2026-08-18
This 1982 study evaluated N-formimidoyl thienamycin (MK0787) against a broad panel of resistant clinical isolates and compared it with several contemporary β-lactam antibiotics. Its strongest contributions were the demonstration of activity against Pseudomonas aeruginosa and Acinetobacter spp., bactericidal effects against gram-negative isolates, and apparent independence from β-lactamase production.
-
MEK1/2, c-Myc, and TERT in Human Stem Cells
2026-08-18
This preprint identifies a regulatory connection in which MEK1/2–ERK signaling and c-Myc:MAX cooperate to maintain TERT transcription in human embryonic stem cells by limiting PRC2-associated repression. Its findings link kinase signaling, transcription-factor occupancy, and opposing H3K27 methylation and acetylation states at the TERT promoter, offering a mechanistic framework for studying telomere regulation in normal pluripotent cells.
-
Caspofungin Workflows for Resistant Candida
2026-08-17
Build resistance-aware Candida assays around Caspofungin, a lipopeptide antifungal drug that targets β-(1,3)-D-glucan production. This guide connects susceptibility testing with delayed-treatment models, comparator design, and practical troubleshooting for translational antifungal therapeutics research.
-
Ivermectin: Mechanism, Evidence, and Research Limits
2026-08-17
Ivermectin is a broad-spectrum anti-parasitic agent used in approved therapies for selected nematode and ectoparasite infections. This article separates established pharmacology and product specifications from unsupported extensions, including claims about cancer or COVID-19.